Annual EBITDA
-$52.15 M
+$6.18 M+10.60%
December 31, 2023
Summary
- As of February 24, 2025, CKPT annual EBITDA is -$52.15 million, with the most recent change of +$6.18 million (+10.60%) on December 31, 2023.
- During the last 3 years, CKPT annual EBITDA has fallen by -$28.95 million (-124.77%).
- CKPT annual EBITDA is now -281.84% below its all-time high of -$13.66 million, reached on December 31, 2015.
Performance
CKPT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$9.72 M
-$3.05 M-45.72%
September 30, 2024
Summary
- As of February 24, 2025, CKPT quarterly EBITDA is -$9.72 million, with the most recent change of -$3.05 million (-45.72%) on September 30, 2024.
- Over the past year, CKPT quarterly EBITDA has stayed the same.
- CKPT quarterly EBITDA is now -198.19% below its all-time high of -$3.26 million, reached on March 31, 2016.
Performance
CKPT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$37.51 M
-$2.02 M-5.70%
September 30, 2024
Summary
- As of February 24, 2025, CKPT TTM EBITDA is -$37.51 million, with the most recent change of -$2.02 million (-5.70%) on September 30, 2024.
- Over the past year, CKPT TTM EBITDA has stayed the same.
- CKPT TTM EBITDA is now -919.68% below its all-time high of -$3.68 million, reached on September 30, 2015.
Performance
CKPT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CKPT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.6% | 0.0% | 0.0% |
| 3 y3 years | -124.8% | 0.0% | 0.0% |
| 5 y5 years | -41.9% | 0.0% | 0.0% |
CKPT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +10.6% | -45.7% | +67.3% | -5.7% | +48.0% |
| 5 y | 5-year | -124.8% | +10.6% | -191.1% | +67.3% | -72.0% | +48.0% |
| alltime | all time | -281.8% | +10.6% | -198.2% | +67.3% | -919.7% | +48.0% |
Checkpoint Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.72 M(+45.7%) | -$37.51 M(+5.7%) |
| Jun 2024 | - | -$6.67 M(-39.0%) | -$35.49 M(-21.2%) |
| Mar 2024 | - | -$10.95 M(+7.7%) | -$45.01 M(-13.7%) |
| Dec 2023 | -$52.15 M(-10.6%) | -$10.17 M(+32.0%) | -$52.15 M(-11.0%) |
| Sep 2023 | - | -$7.70 M(-52.4%) | -$58.62 M(-4.8%) |
| Jun 2023 | - | -$16.20 M(-10.4%) | -$61.59 M(+3.4%) |
| Mar 2023 | - | -$18.08 M(+8.6%) | -$59.55 M(+2.1%) |
| Dec 2022 | -$58.33 M(+2.8%) | -$16.64 M(+56.1%) | -$58.33 M(-18.4%) |
| Sep 2022 | - | -$10.66 M(-24.7%) | -$71.46 M(-0.9%) |
| Jun 2022 | - | -$14.16 M(-16.0%) | -$72.07 M(+7.5%) |
| Mar 2022 | - | -$16.86 M(-43.4%) | -$67.07 M(+18.2%) |
| Dec 2021 | -$56.72 M(+144.5%) | -$29.77 M(+164.0%) | -$56.72 M(+52.5%) |
| Sep 2021 | - | -$11.28 M(+23.2%) | -$37.20 M(+20.5%) |
| Jun 2021 | - | -$9.16 M(+40.5%) | -$30.86 M(+17.0%) |
| Mar 2021 | - | -$6.52 M(-36.4%) | -$26.38 M(+13.7%) |
| Dec 2020 | -$23.20 M | -$10.24 M(+107.2%) | -$23.20 M(+6.3%) |
| Sep 2020 | - | -$4.94 M(+5.8%) | -$21.82 M(-1.3%) |
| Jun 2020 | - | -$4.67 M(+39.9%) | -$22.11 M(-0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$3.34 M(-62.3%) | -$22.26 M(-10.4%) |
| Dec 2019 | -$24.85 M(-32.4%) | -$8.86 M(+69.2%) | -$24.85 M(-10.9%) |
| Sep 2019 | - | -$5.23 M(+8.4%) | -$27.89 M(-13.0%) |
| Jun 2019 | - | -$4.83 M(-18.6%) | -$32.04 M(-5.5%) |
| Mar 2019 | - | -$5.93 M(-50.1%) | -$33.89 M(-7.8%) |
| Dec 2018 | -$36.74 M(+61.3%) | -$11.89 M(+26.7%) | -$36.74 M(+19.3%) |
| Sep 2018 | - | -$9.39 M(+40.6%) | -$30.79 M(+12.6%) |
| Jun 2018 | - | -$6.68 M(-24.0%) | -$27.35 M(+0.8%) |
| Mar 2018 | - | -$8.78 M(+47.9%) | -$27.14 M(+19.2%) |
| Dec 2017 | -$22.77 M(+3.0%) | -$5.94 M(-0.2%) | -$22.77 M(-9.5%) |
| Sep 2017 | - | -$5.95 M(-8.1%) | -$25.16 M(+3.4%) |
| Jun 2017 | - | -$6.47 M(+46.6%) | -$24.34 M(+4.6%) |
| Mar 2017 | - | -$4.41 M(-47.0%) | -$23.27 M(+5.2%) |
| Dec 2016 | -$22.12 M(+61.9%) | -$8.32 M(+62.3%) | -$22.12 M(+2.0%) |
| Sep 2016 | - | -$5.13 M(-5.1%) | -$21.68 M(+7.2%) |
| Jun 2016 | - | -$5.41 M(+65.7%) | -$20.23 M(+36.5%) |
| Mar 2016 | - | -$3.26 M(-58.6%) | -$14.83 M(+28.2%) |
| Dec 2015 | -$13.66 M | -$7.89 M(+114.4%) | -$11.56 M(+214.4%) |
| Sep 2015 | - | -$3.68 M | -$3.68 M |
FAQ
- What is Checkpoint Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Checkpoint Therapeutics?
- What is Checkpoint Therapeutics annual EBITDA year-on-year change?
- What is Checkpoint Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Checkpoint Therapeutics?
- What is Checkpoint Therapeutics quarterly EBITDA year-on-year change?
- What is Checkpoint Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Checkpoint Therapeutics?
- What is Checkpoint Therapeutics TTM EBITDA year-on-year change?
What is Checkpoint Therapeutics annual EBITDA?
The current annual EBITDA of CKPT is -$52.15 M
What is the all time high annual EBITDA for Checkpoint Therapeutics?
Checkpoint Therapeutics all-time high annual EBITDA is -$13.66 M
What is Checkpoint Therapeutics annual EBITDA year-on-year change?
Over the past year, CKPT annual EBITDA has changed by +$6.18 M (+10.60%)
What is Checkpoint Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CKPT is -$9.72 M
What is the all time high quarterly EBITDA for Checkpoint Therapeutics?
Checkpoint Therapeutics all-time high quarterly EBITDA is -$3.26 M
What is Checkpoint Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CKPT quarterly EBITDA has changed by $0.00 (0.00%)
What is Checkpoint Therapeutics TTM EBITDA?
The current TTM EBITDA of CKPT is -$37.51 M
What is the all time high TTM EBITDA for Checkpoint Therapeutics?
Checkpoint Therapeutics all-time high TTM EBITDA is -$3.68 M
What is Checkpoint Therapeutics TTM EBITDA year-on-year change?
Over the past year, CKPT TTM EBITDA has changed by $0.00 (0.00%)